Navigation Links
AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections (NSTI)
Date:8/5/2014

NESS ZIONA, Israel, August 5, 2014 /PRNewswire/ --

Atox Bio today announced that the European Commission has granted AB103 (Sodium acetate salt of the synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH) orphan medicinal product designation (EU/3/14/1294) for the treatment of necrotizing soft tissue infections. Atox Bio is represented in the EU by Dr. Ulrich Granzer as agent.

In addition to a 10-year period of marketing exclusivity in the EU after product approval, orphan designation provides fee reduction for companies seeking protocol assistance from the EMA, direct access to centralized marketing authorization as well as fee reduction for the centralized marketing authorization.

NSTI are rare, fast progressing infections that result in significant tissue destruction and systemic disease leading to multiple organ dysfunction. Currently, there are no approved treatments for NSTI and the standard of care includes prompt and repeated surgical debridement, aggressive resuscitation and physiologic support, in addition to antibiotics.

AB103, a novel immunomodulator, is a short peptide that modulates the host's inflammatory response through binding to the CD28 dimer interface. It offers a unique approach in the treatment of infectious diseases by modulating, but not inhibiting, the host immune system. This approach of targeting the host response rather than the pathogen precludes the rapid generation of drug resistance and provides a multisystem solution for bacterial infections with broad-spectrum coverage, independent of pathogen type.

AB103 successfully completed a Phase 2 study in patients with NSTI. The results demonstrated that patients treated with AB103 had a meaningful improvement across multiple end points. Patients treated with AB103 had a faster resolution of organ dysfunction, spent fewer days in the intensive care unit, required fewer days of assisted ventilation and needed fewer surgical procedures to remove infected tissue. A pivotal study is planned for the second half of 2015.

"Obtaining orphan designation for AB103 in the European Union is an important regulatory milestone for Atox Bio, supporting our global development plan after having received Orphan Drug designation and Fast Track status from the FDA. We are continuing development to bring to patients what could be the first therapy for this devastating and rare disease" said Dan Teleman, Chief Executive Officer of Atox Bio.

http://www.atoxbio.com


Media Contact:
Dan Teleman - CEO
Tel: +972-8-648-4111
E-mail: dant@atoxbio.com


'/>"/>
SOURCE Atox Bio
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Broad Patent Protection Granted for iBio Immunomodulator
3. BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication
4. QRxPharma Granted Additional US Patent on MoxDuo®
5. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
6. Unilife Granted Key U.S. Patent for Unifill Prefilled Syringe
7. Vomaris patent estate grows to six issued U.S. patents and three granted international patents with U.S. Pat. No. 8,224,439
8. OncoSec Granted New Patent from China
9. Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
10. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
11. Harvest Technologies Corporation Granted CE Mark for Expanded Clinical Indication for Treatment of No-Option Critical Limb Ischemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Research and Markets has ... Ischemic Stroke Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Ischemic Stroke epidemiology, Acute Ischemic ...
(Date:5/4/2016)... 2016 Research and ... Actinic Keratosis Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Landscape Highlights 2016, provides comprehensive insights into ... Actinic Keratosis market valuations and forecast, Actinic ...
(Date:5/3/2016)... 2016 Global Insulin Needles ... 09 key companies and supported with 272 tables ... study on the current state of the Insulin ... industry including definitions, classifications, applications and industry chain ... for the international market including development history, competitive ...
Breaking Medicine Technology:
(Date:5/5/2016)... Utah (PRWEB) , ... May 05, 2016 , ... ... life support certifications, is pleased to announce its new referral program, giving participants ... , “Healthcare is a tight-knit community, and we know many professionals share resources ...
(Date:5/5/2016)... ... May 05, 2016 , ... MAP Health ... announced today that Enlightened Solutions has joined the Premier Outcomes-Driven Provider Network. By ... continuum for their patients being treated for substance use. , Enlightened Solutions was ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Linfield College Online ... BSN degree program by waiving the $50 application fee for all qualified applicants from ... Nurses Week Fee Waiver option when applying . , With the ...
(Date:5/5/2016)... ... , ... Augusta Public Schools has teamed with CareDox to provide confidential and ... offices to streamline and bolster care for district students. , Augusta School District, ... schools serve 2,300 students among its six schools. , Monica Guilliams, BSN, RN, ...
(Date:5/5/2016)... ... May 05, 2016 , ... BloodHub, the nation’s ... service orders. Blood suppliers and their hospitals use BloodHub for order management, ... active users across 2,100 hospitals who use our platform to processes thousands of ...
Breaking Medicine News(10 mins):